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Dear Sir,
We thankDr. Antonio J. Carcas-Sansuán for his valuable com-
ments. However, there is an important difference between the
Madrid models and the Leiden models. In their article
(Almeida-Paulo et al.) [1], linear regression limited sampling
strategies for AUC12 prediction were developed and not lim-
ited sampling maximum a priori (MAP) Bayesian estimation
models. Linear regression limited sampling strategies are in-
convenient in a way that it requires strict adherence to set
times for blood sample collection which is almost impossible
in clinical practice. Erroneous predictions will occur if the
sampling times are not exactly as requested in the sampling
protocol. In contrast, maximum a priori (MAP) Bayesian pop-
ulation pharmacokinetic models as we have developed in our
recent article [2] are far more flexible and can handle sampling
times which deviate from the sampling protocol without
resulting in erroneous predictions. Although these models re-
quire more complex calculations and the development of a
population pharmacokinetic model, we believe these models
are superior to linear regression limited sampling formulas
when used in clinical practice. Currently different software
packages are available to support these population
phamacokinetic models in clinical practice and have been
evaluated recently [3]. Furthermore, different more user
friendly web-based initiatives are emerging such as Dose Me
[4] and Insight-rx [5]. In our University Medical Center, we
have used these kinds of models for over a decade in routine
clinical practice for prediction of cyclosporine, tacrolimus,
and mycophenolic acid exposure for all renal and liver trans-
plant recipients with satisfactory results. Furthermore, Størset
et al. [6, 7] recently showed that computerized dose individu-
alization improved target concentration achievement of tacro-
limus after renal transplantation potentially improve long-term
outcome. We agree with Dr. Antonio J. Carcas-Sansuán that
hard evidence that AUC12 monitoring of tacrolimus is superi-
or to troughmonitoring is still lacking when looking at clinical
endpoints. However, based on theory and examples from clin-
ical practice, we strongly believe that AUC12 monitoring of
tacrolimus is more informative and accurate and should there-
fore be applied. The development of dried blood spot tech-
niques [8, 9] has also made the limited sampling AUC12 for
patient less burdensome because the blood sampling can now
be performed at home. To gain more evidence with respect to
improvement of clinical outcome using these models, we
would suggest to set up a two arm randomized clinical trial
in a high acute rejection risk patient population to evaluate the
differences in acute rejection episodes and renal function de-
cline over a period of for instance 5 years between the trough
monitoring arm and the limited sampling AUC12 monitoring
arm. Such a study would be able to provide indisputable evi-
dence for potential additional value of AUC12 over trough
monitoring; however, it will be challenging to finance such a
study with a high sample size and long-term follow-up.
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